Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
The Myeloma Investment Fund (MIF) is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits are reinvested back into research for more effective treatments until there is a cure for every patient.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences2
Q&A
- What is Myeloma Investment Fund's primary investment focus?
- Myeloma Investment Fund focuses on the Health Tech & Life Sciences sector, with both of its portfolio companies operating in this area.
- Can you name some of Myeloma Investment Fund's portfolio companies?
- Myeloma Investment Fund's portfolio includes KAHR Medical, which develops fusion proteins for treating cancer and autoimmune diseases.
- When did Myeloma Investment Fund make its most recent investment?
- Myeloma Investment Fund made its most recent investment in May 2023.
- What was Myeloma Investment Fund's first recorded investment?
- Myeloma Investment Fund's first recorded investment occurred in November 2022.
- What is the total amount raised by Nectin Therapeutics, a portfolio company of Myeloma Investment Fund?
- Nectin Therapeutics, a portfolio company of Myeloma Investment Fund, has raised $36M.
- What is the total amount raised by KAHR Medical, a portfolio company of Myeloma Investment Fund?
- KAHR Medical, a portfolio company of Myeloma Investment Fund, has raised $118.27M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019 |
|---|